Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGhT: INdividualized Screening Trial of Innovative Glioblastoma Therapy
NCT02977780Phase 2Recruiting
- Start
- Feb 2017
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib, neratinib, cc-115 and QBS10072S in glioblastoma (GBM) and Gliosarcoma (GS) (5 arms). Primary endpoint: Overall Survival at 2 years. Started Feb 2017; status: recruiting.
02
Drugs
abemaciclibneratinibcc-115QBS10072S
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02977780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977780.